PriceTargets.com logo

Senseonics - SENS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 247.46%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.58 As of 12/30/2024 12:00 PM ET
▼ -0.0166 (-2.80%)

This chart shows the closing price for SENS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Senseonics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SENS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SENS

Analyst Price Target is $2.00
▲ +247.46% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Senseonics in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 247.46% upside from the last price of $0.58.

This chart shows the closing price for SENS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Senseonics. This rating has held steady since July 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/7/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/5/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/30/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.00 ➝ $2.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$2.00 ➝ $2.00
11/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$2.00
8/15/2023HC WainwrightLower TargetBuy ➝ Buy$3.00 ➝ $2.00
7/19/2023Jefferies Financial GroupInitiated CoverageUnderperform$0.50
7/25/2022HC WainwrightLower TargetBuy$6.00 ➝ $3.00
3/22/2022Colliers SecuritiesReiterated RatingBuy
8/19/2021HC WainwrightInitiated CoverageBuy$6.00
8/10/2021Colliers SecuritiesReiterated RatingBuy$4.00
4/1/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$3.00
3/11/2021Raymond JamesReiterated RatingMarket Perform ➝ Underperform
3/5/2021Stifel NicolausBoost TargetBuy$1.00 ➝ $2.50
3/5/2021Leerink PartnersBoost TargetOutperform$1.00 ➝ $3.00
3/5/2021Raymond JamesDowngradeMarket Perform ➝ Underperform
1/26/2021Stifel NicolausReiterated RatingBuy$1.85
1/20/2021BTIG ResearchDowngradeBuy ➝ Neutral
1/20/2021Craig HallumDowngradeHold ➝ Sell
12/23/2020BTIG ResearchReiterated RatingBuy$1.00
8/16/2020Raymond JamesReiterated RatingHold
8/11/2020Craig HallumUpgradeSell ➝ Hold
8/10/2020BTIG ResearchUpgradeNeutral ➝ Buy$1.00
6/10/2020BTIG ResearchReiterated RatingHold
6/10/2020Stifel NicolausLower TargetBuy$1.85 ➝ $1.00
6/10/2020Leerink PartnersLower TargetOutperform$2.00 ➝ $1.00
5/21/2020UBS GroupLower TargetSell$0.70 ➝ $0.25
4/22/2020BTIG ResearchReiterated RatingHold ➝ Neutral
3/27/2020Craig HallumDowngradeSell$0.40
3/13/2020BTIG ResearchDowngradeBuy ➝ Neutral
3/13/2020GuggenheimDowngradeBuy ➝ Neutral
(Data available from 12/30/2019 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2024
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2024
  • 0 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2024

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Senseonics logo
Senseonics Holdings, Inc., a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Read More

Today's Range

Now: $0.58
Low: $0.50
High: $0.59

50 Day Range

MA: $0.36
Low: $0.25
High: $0.59

52 Week Range

Now: $0.58
Low: $0.25
High: $0.75

Volume

3,862,341 shs

Average Volume

3,858,528 shs

Market Capitalization

$342.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Senseonics?

The following Wall Street analysts have issued stock ratings on Senseonics in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for SENS.

What is the current price target for Senseonics?

0 Wall Street analysts have set twelve-month price targets for Senseonics in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 247.5%. HC Wainwright has the highest price target set, predicting SENS will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Senseonics in the next year.
View the latest price targets for SENS.

What is the current consensus analyst rating for Senseonics?

Senseonics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SENS will outperform the market and that investors should add to their positions of Senseonics.
View the latest ratings for SENS.

What other companies compete with Senseonics?

Other companies that are similar to Senseonics include Transcat, Cytek Biosciences, Standard BioTools, EyePoint Pharmaceuticals and Aehr Test Systems. Learn More about companies similar to Senseonics.

How do I contact Senseonics' investor relations team?

Senseonics' physical mailing address is 20451 Seneca Meadows Parkway, Germantown, MD 20876-7005, United States. The company's listed phone number is 301-515-7260 and its investor relations email address is [email protected]. The official website for Senseonics is www.senseonics.com. Learn More about contacing Senseonics investor relations.